Shares of Cardiff Oncology Inc. (CRDF) are up over 25% at $2.21 in premarket trading today, following a business update provided by the clinical-stage biotechnology company.
The company's lead drug candidate is Onvansertib, a PLK1 inhibitor, being evaluated in combination with standard-of-care (SoC) therapeutics in a range of cancers.
A phase II trial of Onvansertib in patients with a RAS-mutated metastatic colorectal cancer, dubbed CRDF-004, is underway, with top line data anticipated in mid-2024.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.